In consultation: Guidance and quality standards
Showing 1 to 8 of 8
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Ianalumab for treating active Sjogren's syndrome ID6634 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Nirogacestat for treating desmoid tumours [ID6453] | Draft guidance | Technology appraisal guidance | |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Draft guidance | Technology appraisal guidance | |
| Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457] | Draft guidance | Technology appraisal guidance | |
| Oveporexton for treating type 1 narcolepsy [ID6622] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ruxolitinib for treating moderate atopic dermatitis ID6602 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409] | Draft guidance | Technology appraisal guidance |